--News Direct--
BenevolentAI Co-Founder Dr. Ivan Griffin shared exciting news with Proactive's Steve Darling regarding the company's collaboration with AstraZeneca. Through this partnership, AstraZeneca has incorporated a novel target for Heart Failure into its discovery portfolio, thanks to BenevolentAI's AI-driven drug discovery platform.
Dr. Griffin emphasized that this achievement marks a significant milestone, as it represents the first target selected from the extended collaboration with AstraZeneca. This underscores the positive progress in Target Identification within the field of Heart Failure treatment.
The collaboration between BenevolentAI and AstraZeneca began in 2019, initially focusing on discovering potential treatments for idiopathic pulmonary fibrosis and chronic kidney disease. Building on this success, the collaboration expanded in January 2022 to include Heart Failure and Systemic Lupus Erythematosus, showcasing the versatility of BenevolentAI's platform across multiple therapeutic areas.
One of the key strengths of this collaboration is its innovative structure, which brings together scientists and technologists from both companies to work collaboratively. By combining BenevolentAI's AI-driven platform and biomedical knowledge with AstraZeneca's scientific expertise, the collaboration has yielded novel and robust Target Identification strategies.
Overall, the advancement in Heart Failure treatment discovery reflects the commitment of BenevolentAI and AstraZeneca to leveraging cutting-edge technology and collaborative efforts to address unmet medical needs and improve patient outcomes.
Contact Details
Proactive North America
+1 604-688-8158
NA-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/benevolentai-and-astrazeneca-advance-heart-failure-treatment-discovery-857197925
